We have located links that may give you full text access.
JOURNAL ARTICLE
REVIEW
Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines.
Cancer Immunology, Immunotherapy : CII 2002 January
The tumour antigen ErbB-2 belongs to the epidermal growth factor receptor family. Numerous studies have shown that ErbB-2 is overexpressed in many cancers and it is prognostically important in a subset of malignancies. It is well recognised that this receptor has many characteristics that make it an excellent target for tumour-specific immunotherapy. One anti-ErbB-2 monoclonal antibody, Herceptin or TrastuzuMab, has already shown clinical efficacy for the treatment of metastatic breast cancer. However, despite this success, it is still currently unclear how monoclonal antibodies inhibit tumour growth in vivo. This review will summarise the biological activities of a range of anti-ErbB-2 Mabs, as well as their possible mechanisms of action. In addition, as an active mode of immunotherapy, the current vaccine strategies for inducing or enhancing ErbB-2-specific immunity will also be discussed. It is anticipated that a better understanding of the activities of anti-ErbB-2 Mabs will aid in the development of both passive and active immunotherapies against this important receptor.
Full text links
Related Resources
Trending Papers
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Anti-Arrhythmic Effects of Heart Failure Guideline-Directed Medical Therapy and Their Role in the Prevention of Sudden Cardiac Death: From Beta-Blockers to Sodium-Glucose Cotransporter 2 Inhibitors and Beyond.Journal of Clinical Medicine 2024 Februrary 27
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app